OBJECTIVES: To describe epidermal growth factor receptor (EGFR) mutation (EGFRm) testing practices and treatment patterns in EGFRm-positive patients with advanced/metastatic non-small cell lung cancer (NSCLC) and evaluate clinical outcomes. METHODS: Data were drawn from a cross-sectional, retrospective chart review of adult patients with advanced/metastatic NSCLC in Argentina, Belgium, Brazil, India, the Netherlands, Russia, Singapore, Switzerland, and Türkiye between June-September 2021. Eligible patients had an initial advanced/metastatic stage NSCLC diagnosis, and positive first EGFRm test between April 2017-March 2018. Data were reported from NSCLC diagnosis to end of follow-up (June-2020) or death. Index was the receipt date of EGFRm result. Analyses were descriptive. RESULTS: Overall, 208 physicians reported data on 947 patients. Mean (standard deviation) age at diagnosis was 60.3 (10.9) years and 79.4% had an ECOG 0-1. EGFRm was identified by single-gene (64.0%) and multi-gene (36.0%) panel testing. Median (interquartile range) turnaround time was 14 (10-22) days. Prior to and following index, 26.9% and 68.6% of patients, respectively, were administered EGFR-tyrosine kinase inhibitors (EGFR-TKI) as first-line (1 L) treatment. Disease progression occurred in 60.4% and 70.1% pre-index and post-index, respectively. Among those receiving 1 L EGFR-TKI, partial response was reported in 56.5% of patients pre-index and in 65.0% post-index. The median overall survival on post-index 1 L EGFR-TKI was not reached. CONCLUSION: EGFRm status was mostly determined by single-gene testing, and around one-quarter of patients were prescribed pre-index 1 L EGFR-TKI. Further research into outcomes for EGFRm-positive patients not receiving 1 L EGFR-TKI, and pre-index vs post-index treatment would be valuable.
Samol et al. (Thu,) studied this question.